Analysis of HER‐2+ breast cancer patients who were treated with the monoclonal antibody trastuzumab has revealed that the antibody treatment has increased the elicitation of endogenous anti‐HER‐2 antibodies and has also increased the anti‐HER‐2 CD4 T‐cell responses [129, 130]. This evidence concerns the gene ERBB2 and breast carcinoma.